CompletedNCT00195780
Long-term divalproex ER safety for mania in young people ages 10–17 with bipolarity I
About this title
A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
Read the official source — NCT00195780Medication studyAges 10–17United States
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
- Listed locations
- San Diego and 28 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateFebruary 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 227
- Sponsor
- Abbott
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00195780
- Official title
Show the full official title
An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
Get this study by email
Recruitment & locations
CompletedSan Diego · San Marcos · Altamonte Springs
25 more locations
- Fort Lauderdale
- Gainesville
- North Miami
- Winter Park
- Decatur
- Eagle
- Libertyville
- Terre Haute
- Newton
- Overland Park
- Shreveport
- Bangor
- Baltimore
- Chapel Hill
- Fargo
- Canton
- Cincinnati
- Lyndhurst
- Oklahoma City
- Bala-Cynwyd
- Memphis
- DeSoto
- Houston
- Lake Jackson
- Bellevue
Questions about this study
Who is behind this study?
The study sponsor is Abbott.
Did this study involve medication?
Yes. The study involved medication, including Divalproex Sodium (Depakote ER).
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria applied.
